Frovatriptan (succinate hydrate)

Frovatriptan is an agonist of the serotonin (5-HT) receptor subtypes 5-HT1B and 5-HT1D (Kis = 2.51 and 3.98 nM, respectively). It is selective for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2C, 5-HT3, and 5-HT7 receptors, as well as dopamine D1, D2, and D3, histamine H1, and alpha1-adrenergic receptors (Kis = >50 nM). Frovatriptan induces contractions in human basilar arteries isolated post-mortem, coronary arteries from transplant recipient hearts, and coronary arteries from donor hearts unsuitable for transplantation (EC50s = 13.8, 41.69, and 15.49 nM, respectively). It increases carotid vascular resistance in closed-chest and open-chest anesthetized dogs (ED50s = 6 and 1 nmol/kg, i.v., respectively). Formulations containing frovatriptan have been used in the treatment of migraines.Formal Name: butanedioic acid, compd. with (R)-2,3,4,9-tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide, hydrate (1:1:1). CAS Number: 158930-17-7. Molecular Formula: C14H17N3O . C4H6O4 [H2O]. Formula Weight: 379.4. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 3mg/mL, DMSO: 10mg/mL, PBS (pH 7.2): 5mg/mL. lambdamax: 245, 278 nm. SMILES: O=C(N)C1=CC2=C(NC3=C2C[C@H](NC)CC3)C=C1.OC(CCC(O)=O)=O.O. InChi Code: InChI=1S/C14H17N3O.C4H6O4.H2O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13,5-3(6)1-2-4(7)8,/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18),1-2H2,(H,5,6)(H,7,8),1H2/t9-,,/m1../s1. InChi Key: CUETXFMONOSVJA-KLQYNRQASA-N.